SSGJ-707 is a bispecific recombinant humanized IgG4 monoclonal antibody inhibitor that targets PD-1 and VEGF. It is applicable in cancer research, particularly for advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer.
Target:
VEGFR|||PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
